Yissum - Research Development Company of the Hebrew University

Nano-Particles for Intranasal Delivery of Biodegradable Neuropeptide

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology


Project ID : 6-2014-3054

Yissum - Research Development Company of the Hebrew University
Yissum - Research Development Company of the Hebrew University

Description of the technology


Life Sciences and Bio Technology


Nanoparticles, Neuropeptides, Intranasal delivery

Current development stage

TRL4 - POC & Safety of candidate drug formulation is demonstrated in defined animal model


  • Emulsification in aqueous media is not effective for the encapsulation of hydrophilic drugs. Peptides and proteins may deteriorate when exposed to aqueous-organic interfaces
  • Neuropeptides are potent CNS neuromodulators and have many potential clinical uses.
  • Currently no neuropeptides are being used to treat CNS disorders due to their lack of BBB penetration and rapid metabolism in nearly all tissue compartments.

Our Innovation

A new non-invasive biodegradable neuropeptide nanoparticulate system for a brain delivery of peptides via nasal spray to the olfactory tissue.

  • Easy to separate dry powder formulation
  • A dry powder formulation which is fast dispersed in water with desirable drug release
  • Fast disperse to water into uniform nano-dispersion
  • Enhancement of CNS neuropeptide delivery and site specific bioavailability of CNS neuropeptide
  • Non-immunogenic, non-mitotic, enhances olfactory nerve uptake, protect neuropeptide against metabolism
  • Reproducible technique for largescale production


  • Biodegradable Neuropeptide Nanoparticles (TRH) is found to be effective in alleviation of depression and epilepsy but its entry into brain is limited due to its hydrophilic nature and large size as these properties make it unsuitable to pass through BBB.
  • Nose to brain delivery was found to be a potential route for brain delivery bypassing the brain blood barrier. Nanoparticles of sufficiently small size could be transported via axonal pathway through the olfactory bulb into the olfactory cortex and from there to the caudal pole of the cerebral hemisphere, cerebrum and the cerebellum.
  • An effective treatment for CNS disorders will require sustained action of TRH but its short half-life (around 5 min) does not allow it to be effective for long time. Therefore, a delivery of TRH as polymeric nanoparticles will provide a more prolonged release of TRH.

Fig. 1: Intranasal delivery of neuropeptides loaded

Fig. 2: TRH loaded PSA NPs


  • Potentially effective treatment for CNS disorders like depression and epilepsy
  • The formulation could be used as a promising protein and peptide drug carriers for drug delivery systems.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Abraham Domb
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Drug delivery

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.